Lv5
840 积分 2021-01-20 加入
PEG is back: revisiting the role of pegylated interferon alfa and benchmarking its place in HBV cure strategies
1天前
求助中
Recovery of HBV-specific B cell function after discontinuation of nucleos(t)ide analogue therapy: new insight and future challenges
2天前
求助中
Immune checkpoint inhibitors and the liver: balancing therapeutic benefit and adverse events
1个月前
已完结
Immune checkpoint inhibitors in hepatocellular carcinoma: emerging challenges in clinical practice
1个月前
已完结
Role of Immune Cells in Hepatitis B Virus and Associated Sequelae
2个月前
已完结
T cells engineered to carry a high-affinity HBV-specific T cell receptor: a potent weapon against advanced HBV-related HCC
3个月前
已完结
BiTE: A new class of antibodies that recruit T-cells
3个月前
已完结
Where Is the Future of Adjuvant Therapy for Hepatocellular Carcinoma?
4个月前
已完结
Engineered monoclonal antibody tobevibart enhances HBsAg capture by Fc receptor-positive cells and activates HBV-specific T cells
4个月前
已完结
Immune checkpoint inhibitors and the liver: balancing therapeutic benefit and adverse events
4个月前
已完结
皖公网安备34019202002308
